Today's Date
A Phase 2a Trial Of Teplizumab And RN168 In Patients With New Onset Type 1 Diabetes Mellitus
(
ProventionBio
)
ITN Protocol #:
ITN831AI
Branded Name:
ProventionBio
Treatment Protocol #:
Therapeutic Area:
Type 1 Diabetes
Current Status:
Terminated
Summary:
An Open Label Study to Evaluate the Safety of Teplizumab (PRV-031) in At Risk Relatives who Develop Diabetes
Clinical Operations Manager
ITN Biologist
Study Personnel:
